Patents Examined by Shirley V. Gembeh
  • Patent number: 10336966
    Abstract: The present invention relates to a composition having improved or enhanced fidelity and/or longevity of the fragrance profile, comprising fragrance materials in a diamond construction and at least one substantially non-odorous fragrance modulator. The invention also relates to methods of use of the compositions for perfuming suitable substrates, including hard surfaces and body parts, particularly skin and hair.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: July 2, 2019
    Assignee: The Procter & Gamble Company
    Inventors: Lynette Anne Makins Holland, Christelle Marie Sandrine Bonnet, Fabienne Pastor, Jose Maria Velazquez Mendoza, Jonathan Richard Stonehouse, William Eoghan Staite, David Thomas Stanton, Oreste Todini, Stephen Robert Schofield, Sarah Kyakyo Kanyunyuzi Nyakana, Susana Fernandez Prieto, Johan Smets, Jeffrey John Scheibel, Isabelle Guimet
  • Patent number: 10328066
    Abstract: The present disclosure pertains to a pharmaceutical combination comprising (a) an alpha-isoform specific PI3K inhibitor, (b) a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, and (c) an antimetabolite antineoplastic agent; combined preparations and pharmaceutical compositions thereof; the uses of such a combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 25, 2019
    Assignee: Novartis AG
    Inventors: Giordano Caponigro, Thomas Horn-Spirohn, Joseph Lehar
  • Patent number: 10328065
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) alpha-isoform specific PI3K inhibitor and (b) a B-RAF inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 25, 2019
    Assignee: Novartis AG
    Inventors: Giordano Caponigro, Thomas Horn-Spirohn, Joseph Lehar
  • Patent number: 10322139
    Abstract: Formulations of comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a ?-cyclodextrin, e.g., a sulfo butyl ether ?-cyclodextrin, e.g., a ?-cyclodextrin, e.g., a sulfo butyl ether ?-cyclodextrin, e.g., CAPTISOL®; and methods of use in treating CNS disorders.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: June 18, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventor: Kiran Reddy
  • Patent number: 10322097
    Abstract: A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: June 18, 2019
    Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Kam Wai Wong, Yuen Kwan Law, Thomas Efferth, Su-Wei Xu, Sami Hamdoun, Liang Liu
  • Patent number: 10314824
    Abstract: The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: June 11, 2019
    Assignees: Cumberland Pharmaceuticals Inc., Vanderbilt University
    Inventors: Leo Pavliv, Bryan Voss, James West, Erica Carrier
  • Patent number: 10314799
    Abstract: The present invention provides use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus, for example, porcine epidemic diarrhea, porcine transmissible gastroenteritis, rotavirus diarrhea and the like.
    Type: Grant
    Filed: January 17, 2015
    Date of Patent: June 11, 2019
    Assignees: GENIFARM Laboratories Inc, GUANG ZHOU YUAN TU BIOLOGICAL AND CHEMICAL TECHNOLOGY CO. LTD
    Inventors: Yongdong Wang, Jiyuan Cao, Shifa Zhu, Wen Cheng, Zhipeng Huang
  • Patent number: 10314814
    Abstract: A composition comprising 7-hydroxymatairesinol (HMR), or a stereoisomer, salt, complex, adduct or derivative thereof, or an extract containing them for preventing, alleviating or ameliorating the metabolic syndrome conditions.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: June 11, 2019
    Assignee: LINNEA S.A.
    Inventors: Marcello Luzzani, Massimiliano Carreri
  • Patent number: 10307486
    Abstract: The present disclosure relates to surface modified nanocrystalline cellulose (NCC) prepared by chemical modification of NCC as well as its use thereof, including as carrier of particular chemical compounds. The surface of nanocrystalline cellulose (NCC) was modified with chitosan oligosaccharide (CSOS) by selectively oxidizing the primary alcohol moieties of NCC followed by coupling of the amino groups of CSOS to the oxidized NCC to provide the desired material (NCC-CSOS).
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 4, 2019
    Assignee: Celluforce Inc.
    Inventors: Seyedeh Parinaz Akhlaghi, Kam Chiu Tam, Richard M. Berry
  • Patent number: 10300143
    Abstract: Described herein are compositions and methods relating to chemotherapeutic agent conjugates and the treatment of cancer.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: May 28, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Shiladitya Sengupta, Ashish Kulkarni, Poornima Rao, Bhaskar Roy
  • Patent number: 10300054
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: May 28, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Mark Todtenkopf
  • Patent number: 10300073
    Abstract: Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: May 28, 2019
    Assignee: The Regents of the University of California
    Inventors: Dominik Haudenschild, Jasper Yik
  • Patent number: 10292963
    Abstract: Combinations of betaine and vitamin C are used to suppress or prevent malignant tumors or to treat viruses, e.g., by combining the two ingredients in a product consumed by a human, dog, or cat, such as an aqueous liquid such as grape juice, the ingredients being provided in containers with instructions for use, or in finished products, especially with support of tests demonstrating the effectiveness of the treatment for, e.g., preventing tumors in populations known to be at risk of developing tumors, or, treating existing cancers in combination with other cancer drugs such as anastrozole and/or fulvestrant and/or artemisinin either concurrently or sequentially to prevent the cancer from growing when the cancer drug is not being used, or in the treatment of viruses.
    Type: Grant
    Filed: March 16, 2013
    Date of Patent: May 21, 2019
    Inventors: Robert Benson Aylor, Leigh Heather Makover, Robyn Aylor Haines
  • Patent number: 10280179
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterized by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: May 7, 2019
    Assignee: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • Patent number: 10272052
    Abstract: Disclosed herein are compositions and methods for treating tauopathies such as Alzheimer's disease (AD). Also provided herein are methods of reducing or disrupting tau aggregation in a subject, and methods of reducing tau protein in a subject. The methods may include administering to the subject a therapeutic amount of hexachlorophene, or a pharmaceutically acceptable salt thereof. Further provided herein are pharmaceutical compositions comprising hexachlorophene, or a pharmaceutically acceptable salt thereof, for the treatment of a tauopathy in a subject.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: April 30, 2019
    Assignee: University of South Florida
    Inventors: Umesh Kumar Jinwal, Vetriselvan Manavalan
  • Patent number: 10265296
    Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: April 23, 2019
    Assignee: RESPIVANT SCIENCES GMBH
    Inventors: William Gerhart, Pravin Soni, Robert Craig Armstrong
  • Patent number: 10265281
    Abstract: A method for the treatment or prevention of a cardiovascular event in a subject with atherosclerotic vascular disease comprising the step of: b) administering a therapeutically effective amount of a compound of formula (I), a known colchicine derivative and/or a salt thereof wherein: R1, R2, R3, R4, R9, R10, R11 and R12 independently represent hydrogen, C1-4 alkyl, C2-4 alkenyl, C3-6 cycloalkyl, halogen, C1-4 haloalkyl, nitro, amino, C2-4 acylamino, C1-4 alkyl or dialkylamino, hydroxyl, C1-4 alkoxy, C1-4 alkylthio, a group of the formula —SO2N(Rx)2 or SO2Rx where Rx is C1-4 alkyl, C1-4 acyloxy, or optionally substituted phenyl, optionally substituted phenoxy; R7 and R8 independently represent hydrogen, C1-4 alkyl or C1-4 acyl; and R5?, R5?, R6? and R6? independently represent hydrogen, C1-4 alkyl, C2-4 alkenyl, C3-6 cycloalkyl, halogen, C1-4 haloalkyl, nitro, amino, C2-4 acylamino, hydroxyl, C1-4 alkoxy or C1-4 alkylthio a group of the formula —SO2N(Rx)2 or SO2Rx where Rx is C1-4 alkyl, C1-4 acylox
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: April 23, 2019
    Assignee: MURRAY AND POOLE ENTERPRISES LTD
    Inventor: Mark Nidorf
  • Patent number: 10258612
    Abstract: Disclosed are methods and compositions for treating or preventing a disease or disorder responsive to a decrease in baseline mitochondrial iron in a subject in need thereof. The methods typically include administering a pharmaceutical composition comprising a mitochondrial permeable iron chelator to the subject.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: April 16, 2019
    Assignee: Northwestern University
    Inventors: Hossein Ardehali, Hsiang-Chun Chang
  • Patent number: 10238642
    Abstract: The invention relates to methods for treating neurogenic orthostatic hypotension and symptoms thereof using 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: March 26, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventor: Sharathchandra S. Hegde
  • Patent number: 10238625
    Abstract: Methods for the treatment of systemic mast cell related disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 26, 2019
    Assignee: RESPIVANT SCIENCES GMBH
    Inventors: William Gerhart, Pravin Soni, Ahmet Tutuncu